Purification specialist BIA Separations to become part of Sartorius
.jpg)
BIA Separations will be Sartorius's center of excellence for purification of cell and gene therapeutics.
Sartorius has agreed to merge purification specialist BIA Separations into its subgroup Sartorius Stedim Biotech in a transaction totaling 360 million euro.
BIA Separations develops and manufactures market-leading products for purification and analysis of large biomolecules, such as viruses, plasmids and mRNA, which are used in cell and gene therapies and other advanced therapies.
The company's technology for manufacturing scale purification is already in use to produce the first commercialized advanced therapeutics. The company also has a strong presence with such novel drug candidates in the clinical pipeline.
"Combining the teams and technologies of Sartorius and BIA will create a premium offering for the manufacturing of advanced therapies," commented Joachim Kreuzburg, CEO of Sartorius.
Founded in 1998, BIA Separations has invented and commercialized the unique CIM (Convective Interaction Media) monolith chromatography technology. In addition, it offers analytical technologies for process monitoring and optimization.
At its headquarters in Ajdovščina, Slovenia, BIA employs a workforce of some 120 people. Following its strong growth, the company is currently more than quadrupling its production capacity, which will become operational during the beginning of 2021. Furthermore, the company is significantly expanding its market-leading process development services.
Aleš Strancar, founder and CEO of BIA Separations, commented: "I am especially excited that our combined R&D groups will result in one of the strongest development teams in bioprocessing worldwide, which will rapidly increase the number of products under development while substantially reducing time-to-market."
Expecting continued very strong double-digit sales growth over the next few years, BIA is forecasted to earn sales revenue of approximately 25 million euro in 2020.

Related News
-
News WuXi to sell CGT manufacturing unit to US-based Altaris LLC
At the tail end of 2024, Chinese-based CDMO WuXi AppTec announced the signing of their deal with private equity firm Altaris LLC, confirming the sale of WuXi Advanced Therapies, the cell and gene therapy manufacturing arm of WuXi AppTec. -
News Women in Pharma: Our hopes for 2025 and beyond
Our last instalment for 2024 of the Women in Pharma series brings you messages direct from the Informa Markets CPHI team as they discuss the advice and insights they have carried throughout their roles working at CPHI, and what they hope to see for the... -
News CPHI Milan Wrap-Up Report: Conference Highlights
Discover the emerging and trending topics of the pharmaceutical industry with our CPHI Milan Conference Highlights, with exclusive insight from pharmaceutical leaders and experts! -
News BIOSECURE Act not included in key defense spending bill for 2025
On December 7, 2024, the Biden administration revealed the 2025 National Defense Authorization Act, an annual defense bill specifying the budget and expenditures of the US Department of Defense. The controversial BIOSECURE Act was notably missing from ... -
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News Trump 2.0: What does the US election result mean for the healthcare industry?
After Trump won the Presidential election in the US in early November, we take a look at some of the implications a new Trump administration could have on the health and pharmaceutical industry, and on US patients. -
News Women in Pharma: Reflections from Behind the Scenes
In this instalment of our monthly series, the team that brings you the Women in Pharma series each month sits down for a heart-to-heart on what the series means to them, and how they hope to continue their work in the future. -
News Scaling the Industry: CPHI Scale-Up Market interview with YSK Laboratories
For the first time, CPHI Milan hosted the CPHI Start-Up Market, expanding support for emerging and small-sized enterprises in their transition to the next level of growth. In this interview, we spoke with Yuvansh Khokhani, Managing Director of YSK Labo...
Recently Visited
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance